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Abstract: Superovulation protocols are designed to achieve maximum embryo yields. 
Nevertheless, ovarian response control and the quality of obtained embryos is still a 
challenge. On the other hand, to save the superovulated embryos until their subsequent 
use, it is usual to cryopreserve them, so it is also crucial to assess their cryotolerance. 
The aim of this study was to compare the efficacy of a single injection of corifollitropin 
alfa (FSH-CTP) alone or supplemented with hCG and to determine the impact of this 
stimulation on in vitro and in vivo development of fresh or devitrified embryos. Our 
outcomes showed that ovulation rate and recovered embryos were significantly 
increased when hCG was used. In vitro development of fresh and devitrified embryos 
and survival at birth was not significantly affected by superstimulation treatment. 
Results of this study suggest that a single injection of long acting FSH-CTP 
supplemented with hCG can be effectively used in rabbits to elicit an increase in 
ovulation rate and number of recovered embryos. Furthermore, we demonstrated that 
hCG supplementation had no negative effects in embryo cryosurvival and development, 
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Superovulation protocols are designed to ensure the maximum number of transferable 
embryos per donor. Most of the embryos produced by superovulation are cryopreserved 
until they are subsequently used, which allows saving embryos for an unlimited time. 
The human gonadotropins, follicle-stimulating hormone (FSH), luteinizing hormone 
(LH) and human chorionic gonadotropin (hCG) are commonly used for superovulation 
in humans and animals. The effectiveness of superovulation treatments with 
gonadotropins is dependent on maintenance of adequate daily levels of FSH throughout 
the process. The short elimination half-life and rapid metabolic clearance of the 
traditional FSH require twice daily treatments, which increases the donor handling and 
the possibility of errors in giving the treatments. The introduction of corifollitropin alfa 
(FSH-CTP), a long-acting recombinant FSH, has giving an opportunity to simplify 
superstimulation protocols, reducing the number of injections and consequently 
improving the overall donor management. On the other hand, results of superovulation 
treatments vary, and one of the reasons for this may be the variable LH:FSH ratio. 
Although LH has essential and well-established roles in ovarian steroid synthesis and 
ovulation (Chappel and Howles, 1991; Wallach et al. 1995; Sen and Caiazza, 2013), the 
use of LH in superovulation treatments is controversial and unclear. Low LH levels 
might intensify FSH sensitivity in granulosa cells by increasing androgen synthesis 
during the early stage of folliculogenesis, and this activity is required for normal follicle 
and oocyte development (Ruvolo et al. 2007, Durnerin et al. 2008). Moreover, a high 
LH level seems to be detrimental for follicular growth. In some clinical studies, where 
endogenous LH was absent or inactive, recombinant human FSH (rhFSH) alone 
allowed follicle development but with an inadequate estradiol concentration (Lévy et al. 
2000) and embryo quality and implantation rates were significantly higher in recipients 
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of embryos from donors receiving rhFSH in combination with recombinant human LH 
(rhLH) compared with rhFSH alone (Acebedo et al. 2004; Ruvolo et al. 2007; Franco et 
al. 2009). It has been controversy over whether rhLH or hCG should be used for 
superovulation treatments. While hCG has LH-like activity it differs compared with LH 
in its potency and duration of action (Ezcurra and Humaidan, 2014). Although the α-
subunits of LH and hCG show a high degree of similarity, the β-subunit, in the case of 
hCG, has five glycosylation sites more than that of LH. The extra glycosylation sites 
give hCG a longer half-life (Le Cotonnec et al. 1998; Mannaerts et al. 1998). In rabbits, 
the effect of LH on superovulation has been studied using purified porcine FSH, 
obtaining highly variable results (Hashimoto et al. 2004, Salvetti et al. 2007). Our 
studies with recombinant human gonadotropins (rhFSH either alone or in combination 
with rhLH) suggested that the window of LH in rabbits is FSH dose dependent (Viudes-
de-Castro et al. 2015). It seems that the endogenous LH concentration is enough to 
duplicate the ovulation rate of does treated with low FSH doses (Viudes-de-Castro et al. 
2009), but is insufficient to increase follicular recruitment when higher doses of FSH 
are used (Viudes-de-Castro et al. 2015). Recently, we evaluated the ovarian stimulation 
response in rabbit does treated with FSH-CTP versus a traditional rhFSH, either alone 
or in combination with rhLH (Viudes-de-Castro et al. 2017). Results suggested that 
embryos from does treated with FSH-CTP supplemented with LH reached similar in 
vivo development as embryos from no superovulated does. Due to the relatively and 
rapid metabolic clearance of recombinant LH, is a more time-consuming protocol, 
requiring one daily injections to maintain the threshold level during ovarian 
superstimulation. Since the circulating half-life of hCG is 80-fold longer than that of LH 
(Cole, 2010), a single injection of FSH-CTP plus hCG could simplify the superovulation 
application treatment and reduce the donor distress.  






The current study was performed to compare the efficacy of a single injection of 
corifollitropin alfa (FSH-CTP) combined with hCG versus a FSH-CTP alone to 
superovulate rabbit does, and to determine the impact of this stimulation combined with 
embryo cryopreservation on in vitro and in vivo embryo development. 
 
MATERIALS AND METHODS  
 
Animals and ethical statement  
The research was carried out at the experimental farm of the Institute of Science and 
Animal Technology (ICTA), Universitat Politècnica de València. All animals were 
handled in accordance with the principles of animal care published by Spanish Royal 
Decree 53/2013 (BOE 2013) and the Directive 2010/63/EU EEC. The experiments were 
approved by the Ethics and Animal Welfare Committee of the Universitat Politècnica de 
València (procedure 2015/VSC/PEA/00061). 
Ninety-nine nulliparous rabbit does belonging to a New Zealand White line selected for 
litter size at weaning were used (Line A, Estany et al. 1992). Animals were housed in 
flat-deck cages, fed with a standard pellet diet ad libitum and had free access to water. 
An alternating cycle of 16 h lights and 8 h of dark was used. 
 




Ovarian stimulation was induced using Corifollitropin alfa (Elonva, Merck Sharp & 
Dohme S.A.; Spain) either alone or in combination with hCG (Coriogan, Laboratorios 
Ovejero S. A.; León, Spain). Rabbit donors, weighing 3.9 to 4.2 kg, were assigned 
randomly between experimental groups: 
-Group FSH-CTP: 40 rabbit does were subcutaneously treated once with 3 µg of 
Corifollitropin alfa. 
-Group FSH-CTP+hCG: 40 rabbit does were subcutaneously treated once with 3 µg of 
Corifollitropin alfa plus 7.5 UI of hCG. 
Does were inseminated with 1 mL of pooled sperm from fertile males of the same line 
60 h after the first gonadotropin injection, and ovulation was induced with 1 µg 




Females were euthanized 72 h after artificial insemination with an intravenous injection 
of 0.6 g pentobarbital sodium (Dolethal; Vetoquinol, Madrid, Spain), and the 
reproductive tract was immediately removed. Embryos were recovered by perfusion of 
each uterine horn with 10 mL Dulbecco´s phosphate buffered saline (HyClone™ DPBS 
liquid Without Calcium, Magnesium, Phenol Red; HyClone Laboratories, Logan, Utah, 
USA) containing 0.2% bovine serum albumin (AMRESCO® Albumin Bovine, (BSA); 
Solon, USA), 0.133 g/L CaCl2, 0.100 g/L MgCl2 and antibiotics (100 IU/mL Penicillin 
and 0.01 mg/mL streptomycin, Sigma-Aldrich Quimica S.A., Spain). The recovered 
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fluid was collected into sterile Petri dishes for examination under a stereomicroscope. 
Embryos were scored by morphologic criteria according to International Embryo 
Transfer Society classification (IETS). Briefly, only embryos in morula or early 
blastocyst stages with homogenous cellular mass, and spherical mucin coat and zona 
pellucida were catalogued as normal (transferable) embryos. The ovulation rate was 
estimated counting the ovarian follicles with scar under the microscope stereoscope. 
The number of oocytes and the normal and abnormal embryos were recorded.  
 
Embryo vitrification procedure 
Vitrification was carried out in 8 batches. A total of 340 embryos were vitrified and de-
vitrified using the methodology described by Vicente et al. (1999). The vitrification 
procedure was carried out in two steps at 20 °C. In the first step, embryos were placed 
for 2 min in a vitrification solution consisting of 10% (v/v) dimethyl-sulphoxide (1.75M 
DMSO, Sigma-Aldrich Quimica S.A., Spain) and 10% (v/v) ethylene glycol (2.23 M 
EG, Sigma-Aldrich Quimica S.A., Spain) in DPBS supplemented with 0.2% (w/v) of 
BSA. In the second step, embryos were suspended for 1 min in a solution of 20% (v/v) 
DMSO and 20% EG in DPBS supplemented with 0.2% (w/v) of BSA. Then, embryos 
suspended in the vitrification medium were loaded into plastic straws (French 
ministraws, IMV, L’Aigle, France) between two drops of DPBS separated by air 
bubbles. Finally, the straws were sealed and directly plunged into liquid nitrogen.  
De-vitrification procedure was performed by placing the straws to 10 cm from vapour 
nitrogen until vitrified fraction begin to ice formation (milking aspect 20-30 sec) and 
thawed by submerging the straws into a water bath at 20 °C for 10 sec. The vitrification 
medium was removed in two steps. In the first step, the embryos were expelled with the 
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medium into a solution of DPBS with 0.33M sucrose for 5 min, and in the second step 
the embryos were washed in a solution of DBPS for another 5 min. Devitrified embryos 
were scored and only undamaged embryos were catalogued as transferable (334 
undamaged embryos, 98.2% transferable embryos). 
 
In vitro culture until blastocyst stage 
A total of 390 embryos were cultured (192 and 198 embryos from FSH-CTP and FSH-
CTP+hCG group, respectively, of which 173 were fresh and 217 devitrified embryos). 
Eight embryo culture replicates were performed. Embryos were cultured for 48 h in 
Tissue Culture Medium 199 (TCM199) plus 10% Fetal Bovine Serum (FBS, Sigma-
Aldrich Quimica S.A., Spain) supplemented with antibiotics (100 IU/mL Penicillin and 
0.01 mg/mL streptomycin, Sigma-Aldrich Quimica S.A., Spain) at 38.5 °C, 5% CO2 
and saturated humidity. The in vitro development ability of embryos to hatched state 
(more than 50% of mass cell extruded to zona pellucida) was recorded. 
 
Embryo transfer 
A total of 297 embryos were transferred into 19 recipient females (143 and 154 embryos 
from FSH-CTP and FSH-CTP+hCG group, respectively, of which 117 were fresh and 
180 devitrified embryos). Ovulation was induced in the receptive females (according to 
the turgidity and color of the vulva) with 1 µg of buserelin acetate (Hoechst, Marion 
Roussel, Madrid, Spain) given intramuscularly 72 hours before transfer. Synchronous 
females were anaesthetized by intramuscular injection of 16 mg of xylazine (Rompún, 
Bayer AG, Leverkusen, Germany) following intravenous injection of 16-20 mg 
ketamine hydrochloride (Imalgène, Merial SA, Lyon, France). Oviductal embryo 
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transfer was performed using the laparoscopic technique described by Besenfelder and 
Brem (1993). The number of embryos transferred per recipient does was from 12 to 15. 
At the end of the transfer, rabbit does were intramuscular injected with 0.5 mL/doe of 
enrofloxacin (Baytril 5%, Bayer, Barcelona, Spain) brought back to the flat deck cages.  
 
Statistical analysis 
Ovulation rate, number of recovered embryos, abnormal embryos, oocytes and 
blastocysts were analyzed by ANOVA using a general linear model (GLM) procedure 
including the ovarian stimulation treatment (FSH-CTP and FSH-CTP+hCG) as fixed 
effect. For ovulation induction rate, development to blastocyst rate, hatching blastocyst 
rate and survival rate at birth, a probit link with binomial error distribution was used, 
including as fixed effects the ovarian stimulation treatment (FSH-CTP and FSH-
CTP+hCG) and the embryo preservation state (fresh and devitrified). All statistical 
analyses were performed with SPSS software (SPSS 21.0 software package; SPSS Inc., 
2002, Chicago, IL, USA). Results were reported as least-square means (LSM) with 
standard error of the mean. LSM were separated using Fisher´s protected least 




Evaluation of ovarian stimulation treatment on the ovarian response and recovery 
variables 
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As shown in Table 1, the ovarian stimulation treatment did not significantly affect 
ovulation induction rate. However, FSH-CTP+hCG group showed a significant increase 
in ovulation rate and recovered embryos in comparison with FSH-CTP alone group 
(51.1±2.50 vs 42.5±2.72 ovulation rate and 41.4±2.96 vs 28.2±3.23 recovered embryos 
for FSH-CTP+hCG and FSH-CTP, respectively; P<0.05, Table 1). Nevertheless, there 
was not statistical difference in the number of abnormal embryos, oocytes and 
blastocysts between both stimulation treatments.  
 
Evaluation of ovarian stimulation treatment and preservation method on in vitro 
development  
Both FSH-CTP and FSH-CTP+hCG treatments resulted in similar development to 
blastocyst rate, regardless the embryos were fresh or devitrified. Fresh embryos showed 
higher development to blastocyst rate compared with devitrified embryos (Table 2). 
However, the hatching blastocyst rate was similar among superovulation or preservation 
treatments.  
 
Evaluation of embryo viability after transfer 
FSH-CTP+hCG treatment showed similar viability rate at birth than FSH-CTP alone. 
Moreover, embryos of both superstimulation treatments showed the same cryotolerance 
(Table 2).  
 
DISCUSSION  
Version author of manuscript 
11 
 
The FSH-CTP introduction reduces the number of injections needed for ovarian 
stimulation and permits a simpler approach. FSH-CTP has been used successfully in 
women, cattle and rabbits (Devroey et al. 2009; Fauser et al.  2010; Carvalho et al. 
2014, Boostanfar et al. 2015, Viudes de Castro et al. 2017; Vicente et al. 2018). 
Although FSH is the main regulator of ovarian follicle growth and maturation, LH 
induce key changes in both oocyte and follicular cells, that contribute to suitable oocyte 
competence acquisition, with a prominent role in the process of ovulation and in 
subsequent fertilization and implantation process. Therefore, it is common that in 
controlled ovarian stimulation protocols, in an attempt to mimic folliculogenesis, FSH is 
usually administered in combination with LH. In a previous study by our group (Viudes 
de Castro et al. 2017), when treatments with rhFSH and FSH-CTP alone or 
supplemented with rhLH were compared, no differences were observed among 
treatments in the number of transferable embryos. Therefore we found that only the 
FSH-CTP with LH supplementation group reached the implantation rate of the non 
stimulated does. Absence of rhLH seemed to compromise the in vivo viability, showing 
lower implantation and survival rate when FSH-CTP alone was used, suggesting a 
higher embryo competence to implant on FSH-CTP supplemented with LH group. With 
an effective half-life of approximately one day, rhLH is suitable for once-daily SC 
injection, so when FSH-CTP was supplemented with LH, the opportunity to reduce the 
number of injections and consequently the donor stress in ovarian stimulation protocol 
disappeared, main advantage of FSH-CTP introduction. Therefore, a more donor-
friendly approach should be used. LH and hCG share structural similarities and function 
thought the same receptor. In addition, hCG exhibits a markedly longer half-life than 
LH due to the higher number of both glycosylation sites and sialic acid residues 
(Campbell, 2005). In the current work a single dose of FSH-CTP supplemented with 
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hCG is more effective in ovarian stimulation than FSH-CTP alone, maximizing the 
number of transferable embryos recovered and providing similar embryo development 
rate in vitro and survival rate at birth to that of FSH-CTP alone. In contrast to our 
previous study with rhFSH and FSH-CTP alone or supplemented with rhLH where no 
differences in the number of transferable embryos was observed (Viudes de Castro et al. 
2017). These results are similar to those observed by Drakakis et al. (2009) in women, 
who demonstrated the superiority of hCG over rhLH in ovarian stimulation with rhFSH, 
showing significantly higher number of transferable embryos, implantation and 
pregnancy rates when hCG was used. In addition, it seemed that hCG allowed a highly 
effective and more stable occupancy of LH/hCG receptors than rhLH. Moreover, our 
results indicate that superovulation treatment using hCG supplementation do not 
compromise the in vivo embryo cryosurvival, contrary to what was observed in a 
previous study using rhLH supplementation (Vicente et al. 2018). On the other hand, 
regardless the morphological assessment of the embryo can provide certain clues about 
the quality, the potential for in vitro development and certainly the survival rate at birth 
are determinant to identify an effective ovarian stimulation protocol. In the present 
work, embryos obtained from donors superstimulated with FSH-CTP supplemented 
with hCG reached a similar developmental rate in vitro and the survival rate at birth to 
those of FSH-CTP alone. On the other hand, in vitro and in vivo cryosurvival of 
embryos was not affected by the superstimulation treatment.  
Although it is common for ovarian stimulation treatments to trigger anovulatory 
processes and ovulation of donors without normal embryos, in the present study the 
percentage of females that did not respond to ovarian stimulation treatment with FSH-
CTP supplemented with hCG was very low (5%), while a 20% of females who received 
FSH-CTP alone treatment were not induced to ovulate. Additionally, of the seventy 
Version author of manuscript 
13 
 
females induced to ovulate only two donors did not produce normal embryos, one per 
treatment.  
In conclusion, the use of corifollitropin alfa supplemented with hCG maximize the 
number of transferable embryos without affecting their cryosurvival rate at birth and 
reduce the female stress. Therefore, FSH-CTP supplemented with hCG provide an 
effective and more donor-friendly ovulation stimulation protocol.  
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Table 1: Effect of ovarian stimulation treatment on recovery variables. Results are 







Number of females 40 40 
Ovulation induction rate 0.80±0.063 0.95±0.034 
Ovulation rate 42.5±2.72a 51.1±2.50b 
Recovered embryos 28.2±3.23a 41.4±2.96b 
Abnormal embryos 3.2±0.92 3.1±0.85 
Oocytes 1.6±0.48 1.3±0.44 
Blastocysts 0.5±0.44 0.7±0.40 
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Table 2: Effect of ovarian stimulation treatment on embryo development. Results are 














CTP: 3 µg 7.5 UI of hCG;  
n1: number of cultured embryos; n2:  number of transferred embryos. 
a,b  and x,z values in the same column and row with different superscripts are  
statistically different (P<0.05). 
 
Experimental group Development to blastocyst rate 
 n1 Fresh Devitrified 
CTP  192 0.95±0.026a 0.82±0.044b 
CTP+hCG  198 0.99±0.014a 0.79±0.041b 
 Hatching blastocyst rate 
 n1 Fresh Devitrified 
CTP  192 0.54±0.058 0.38±0.056 
CTP+hCG  198 0.45±0.050 0.47±0.050 
 Survival rate at birth 
       n2 Fresh Devitrified 
CTP  143 0.60±0.053x 0.39±0.064y 
CTP+hCG  154 0.62±0.050x 0.45±0.064y 
